Canada’s Cosmetic Animal-Testing Ban: What It Means For China Testing, New Ingredients, USA

Canada’s prohibitions on cosmetic animal testing enter into force in December, largely in line with EU, California and other bans around the globe, but with some notable distinctions. “Now it's really time to increase the pressure in the US – action can't be far behind,” says Brandi Halls, chief ethics officer at Lush Cosmetics, North America.

Beginning on 22 December, no cosmetic product will be permitted for sale in Canada unless its safety can be substantiated without the use of data derived from animal testing after that date.

Passed as part of the Budget Implementation Act (C-47) on 22 June, Canada’s cosmetic animal-testing ban aligns closely with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Canada

More from North America

Washington State TFCA Violators Likely To Face Conversation Before Penalties – DOE

 

The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”

Adcomm Reform: Getting Needed Information More Important Than Vote Or Discussion

 

US FDA Office of New Drugs Director Peter Stein says review divisions have made the case that a discussion-only meeting would solicit the necessary input.

US FDA’s Petition Procedures No Place For OTC Acetaminophen Pediatric Dosing Enforcement

 

Requests for “enforcement actions are not within the scope of FDA’s citizen petition procedures,” CDER says, rejecting petition dosing device firm Parenteral Technologies submitted as it prepares for workshop on Pediatric Research Equity Act requirements for OTC NDA sponsors.